Tesamorelin — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 5 sources[1,2,3,4,5].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Metabolic effects of a growth hormone-releasing factor in patients with HIV | New England Journal of Medicine | 2007 |
| 2 | Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone… | BioDrugs | 1999 |
| 3 | Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a… | Journal of Clinical Endocrinology & Metabolism | 2006 |
| 4 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
| 5 | Stability of protein pharmaceuticals: an update | Pharmaceutical Research | 2010 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 16 | TESA-PIVOTAL-1 · TESA-PIVOTAL-2 · TESA-NAFLD-PH2 · TESA-PIVOTAL-1-DDI · TESA-PIVOTAL-2-PK · TESA-NAFLD-PH2-PK · TESA-PIVOTAL-1-HEPATIC-IMP · TESA-PIVOTAL-2-RENAL-IMP · TESA-NAFLD-PH2-RENAL-IMP · TESA-PIVOTAL-1-RENAL-IMP · TESA-PIVOTAL-2-HEPATIC-IMP · TESA-NAFLD-PH2-HEPATIC-IMP · TESA-PIVOTAL-1-PK · TESA-PIVOTAL-2-DDI and 2 more |
| Evidence syntheses | 2 | Tesamorelin in hiv-associated lipodystrophy and excess… · Tesamorelin in hiv-associated lipodystrophy and excess… |
| Comment periods | 1 | Draft monograph: Tesamorelin |
| Indication assessments | 3 | Lipodystrophy · MASH · GH axis |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375 · PMID 18052660
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12(2):139–157. doi:10.2165/00063030-199912020-00007 · PMID 18031173
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805. doi:10.1210/jc.2005-1536 · PMID 16352683
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.